Aldosterone Blockade Early After Acute Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1603 participants.

Also called NCT01059136

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,603 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01059136
Other papers using this trial's data
  • Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial Journal of the American College of Cardiology, 2016-04-26 DOI, PubMed 27102506

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01059136. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aldosterone Blockade Early After Acute Myocardial Infarction
Acronym
ALBATROSS
Intervention (Drug)
Spironolactone
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct01059136
Content hash
6dc60117d0efb17b26e54672e6249f48ac66dcc464d083c5a8c7e3362d692e0f